Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: The case study of Japan

References

• Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N-9N
   PubMed Web of Science ®Google Scholar
• Akao M, Chun YH, Wada H, et al. Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry. J Cardiol 2013;61:260-6
   PubMed Web of Science ®Google Scholar
• National Institute of Population and Social Security Research. Japanese population in 2010 by age and gender. http://www.ipss.go.jp/. Accessed March 2015
   Google Scholar
• Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949-53
   PubMed Web of Science ®Google Scholar
• Inoue H, Fujiki A, Origasa H, et al. Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination. Int J Cardiol 2009;137:102-7
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8
   PubMed Web of Science ®Google Scholar
• Astellas Pharma, Inc. Almanac 2013/Medical Care and Pharmaceutical Industry. http://www.astellas.com/jp/corporate/information/data.html. Accessed January 2014
   Google Scholar
• Ministry of Health, Labour and Welfare; Ministry of Education, Culture, Sports, Science and Technology. The Stroke Project. http://www.stroke-project.com/data_pref.php. Accessed April 2015
   Google Scholar
• Takahashi S. Nonvalvular atrial fibrillation and stroke. Japan Med Assoc J 2006;49:119-24
   Google Scholar
• Iqbal MB, Taneja AK, Lip GY, et al. Recent developments in atrial fibrillation. BMJ 2005;330:238-43
   PubMed Web of Science ®Google Scholar
• Jorgensen HS, Nakayama H, Reith J, et al. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke 1996;27:1765-9
   PubMed Web of Science ®Google Scholar
• Lamassa M, di Carlo A, Pracucci G, et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 2001;32:392-8
   PubMed Web of Science ®Google Scholar
• Yoneda Y, Okuda S, Hamada R, et al. Hospital cost of ischemic stroke and intracerebral hemorrhage in Japanese stroke centers. Health Policy 2005;73:202-11
   PubMed Web of Science ®Google Scholar
• Kimura K, Minematsu K, Yamaguchi T; Japan Multicenter Stroke Investigators' Collaboration (J-MUSIC). Atrial fibrillation as a predictive factor for severe stroke and early death in 15831 patients with acute ischemic stroke. J Neurol Neurosurg Psychiatry 2005;76:679-83
   PubMed Web of Science ®Google Scholar
• Sakai H, Muramatsu K, Kobori S, et al. How does the accuracy of ICD coding influence for resource consumption under the case mix based evaluation. Asian Pac J Dis Manag 2011;5:19-22
   Google Scholar
• Ministry of Health, Labour and Welfare. Handbook of Health and Welfare Statistics 2014. Table 5-29: medical care expenditure of medical care by inpatient - outpatient, age group and category of disease. http://www.mhlw.go.jp/english/database/db-hh/5-1.html. Accessed October 2015
   Google Scholar
• Camm AJ, Lip GY, de Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation–developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-413
   PubMed Web of Science ®Google Scholar
• JCS Joint Working Group. Guidelines for pharmacotherapy for atrial fibrillation. 2013. http://www.j-circ.or.jp/guideline/pdf/JCS2013_inoue_h.pdf. Accessed February 2014
   Google Scholar
• Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119:8S-21S
   PubMed Web of Science ®Google Scholar
• Warfarin. Summary of Product Characteristics, Teva, 2014
   Google Scholar
• Lu Y, Won KA, Nelson BJ, et al. Characteristics of the amiodarone-warfarin interaction during long-term follow-up. Am J Health Syst Pharm 2008;65:947-52
   PubMed Web of Science ®Google Scholar
• Turpie AG. Warfarin replacements: mechanisms underlying emerging agents. Can J Cardiol 2008;24(Suppl C):56-60C
   Google Scholar
• McBride D, Brüggenjürgen B, Roll S, et al. Anticoagulation treatment for the reduction of stroke in atrial fibrillation: a cohort study to examine the gap between guidelines and routine medical practice. J Thromb Thrombolysis 2007;24:65-72
   PubMed Web of Science ®Google Scholar
• Dantas GC, Thompson BV, Manson JA, et al. Patients’ perspectives on taking warfarin: qualitative study in family practice. BMC Fam Pract 2004;5:1
   PubMedGoogle Scholar
• Maeda K, Sakai T, Hira K, et al. Physicians’ attitudes toward anticoagulant therapy in patients with chronic atrial fibrillation. Intern Med 2004;43:553-60
   PubMed Web of Science ®Google Scholar
• Ikai H, Briere JB, Imanaka Y. Prevention of cardiovascular events related to non-valvular atrial fibrillation (NVAF) in acute care hospitals. JCMI 2009;29(Suppl):1-4
   Google Scholar
• Koretsune Y. Atrial fibrillation and the GARFIELD registry in Japan. Presented at the Japanese Society of Electrocardiology 29th Annual Congress, Oct 13 2012, Chiba, Japan
   Google Scholar
• Okumura K, Komatsu T, Yamashita T, et al. Time in the therapeutic range during warfarin therapy in Japanese patients with non-valvular atrial fibrillation - a multicenter study of its status and influential factors. Circ J 2011;75:2087-94
   PubMed Web of Science ®Google Scholar
• Rivaroxaban (Xarelto) Summary of Product Characteristics. Bayer, Leverkusen, 2013
   Google Scholar
• Patel M, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91
   PubMed Web of Science ®Google Scholar
• Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation. Circ J 2012;76:2104-11
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Technology appraisal guidance 256. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation. 2012
   Google Scholar
• Restovic G, Carcedo D, McLeod EJ, et al. Cost-effectiveness of rivaroxaban versus acenocumarol in the stroke prevention in patients with non-valvular atrial fibrillation in the Spanish setting. Value Health 2012;15:A375
   Google Scholar
• Kourlaba G, Maniadakis N, Andrikopoulos G, et al. Economic evaluation of rivaroxaban in stroke prevention among patients with atrial fibrillation in Greece. Value Health 2012;15:A371
   Google Scholar
• Psenkova M, Lukac M, Mackovicova S, et al. Prevention of stroke in patients with atrial fibrillation: cost-utility analysis of rivaroxaban versus warfarin in Slovakia. Value Health 2012;15:A375
   Google Scholar
• Asukai Y, Duran A, Lloyd A, et al. Cost-effectiveness of rivaroxaban for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors - a UK perspective. Value Health 2012;15:A371
   Google Scholar
• Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices - overview: a report of the ISPOR–SMDM modeling good research practices task force-1. Value Health 2012;15:796-803
   PubMed Web of Science ®Google Scholar
• National Institute of Population and Social Security Research. Population projections for Japan 2011-2060. www.ipss.go.jp. Accessed September 2014
   Google Scholar
• City of Kyoto. Results of National Population Census 2010. http://www.city.kyoto.lg.jp/fushimi/page/0000013497.html. Accessed April 2015
   Google Scholar
• Tomita F, Kohya T, Sakurai M, et al. Prevalence and clinical characteristics of patients with atrial fibrillation: analysis of 20,000 cases in Japan. Jpn Circ J 2000;64:653-8
   PubMedGoogle Scholar
• Ministry of Health, Labour and Welfare. Handbook of Health and Welfare Statistics 2013. http://www.mhlw.go.jp/english/database/db-hh/1-2.html. Accessed October 2014
   Google Scholar
• Komatsu T, Sato Y, Ozawa M, et al. Comparison between CHADS2 and CHA2DS2-VASc score for risk stratification of ischemic stroke in Japanese patients with non-valvular paroxysmal atrial fibrillation not receiving anticoagulant therapy. Int Heart J 2014;55:119-25
   PubMed Web of Science ®Google Scholar
• Ishikawa S, Kayaba K, Gotoh T, et al. Incidence of total stroke, stroke subtypes, and myocardial infarction in the Japanese population: the JMS Cohort Study. J Epidemiol 2008;18:144-50
   PubMed Web of Science ®Google Scholar
• Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689-96
   PubMed Web of Science ®Google Scholar
• Eckman MH, Levine HJ, Pauker SG. Decision analytic and cost-effectiveness issues concerning anticoagulant prophylaxis in heart disease. Chest 1992;102:538S-49S
   Google Scholar
• Fukiyama K, Kimura Y, Wakugami K, et al. Incidence and long-term prognosis of initial stroke and acute myocardial infarction in Okinawa, Japan. Hypertens Res 2000;23:127-35.
   PubMed Web of Science ®Google Scholar
• Ueda K, Hasuo Y, Kiyohara Y, et al. Intracerebral hemorrhage in a Japanese community, Hisayama: incidence, changing pattern during long-term follow-up, and related factors. Stroke 1988;19:48-52
   PubMed Web of Science ®Google Scholar
• Statistics Bureau, Consumer price index 1970–2013. Available at: www.stat.go.jp. Accessed December 2014
   Google Scholar
• Sullivan SD, Mauskopf JA, Augustovski FA, et al. Budget Impact Analysis - Principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health 2014;17:5–14
   PubMed Web of Science ®Google Scholar
• Atarashi H, Inoue H, Okumura K, et al. Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: a report from the J-RHYTHM Registry. Circ J 2011;75:1328-33
   PubMed Web of Science ®Google Scholar
• Ogawa S, Ikeda T, Kitazono T, et al. Present profiles of novel anticoagulant use in Japanese patients with atrial fibrillation: insights from the Rivaroxaban Postmarketing Surveillance Registry. J Stroke Cerebrovasc Dis 2014;23:2520-6
   PubMed Web of Science ®Google Scholar
• Ministry of Health, Labour and Welfare. Revision of medical fees in 2014. www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000032996.html. Accessed March 2015
   Google Scholar
• Medical Fee Ministerial Notification No.76 of the Ministry of Health, Labour and Welfare on March 5th, 2012. http://www.mhlw.go.jp. Accessed November 2012
   Google Scholar
• Hori M, Koretsune Y, Yasaka M, et al. Pharmacoeconomic analysis of dabigatran etexilate for prevention of stroke in patients with non-valvular atrial fibrillation. Pharma Medica 2011;29:151-64
   Google Scholar
• Hattori N, Hirayama T, Katayama Y. Medical care for chronic-phase stroke in Japan. Neurol Med Chir (Tokyo) 2012;52:175-80
   PubMed Web of Science ®Google Scholar
• Kobayashi S, ed. Japanese Stroke Data Bank 2009. Tokyo: Nakayama Shoten, 2009 [In Japanese]
   Google Scholar
• Tanihata S, Nishigaki K, Kawasaki M, et al. Outcomes of patients with stable low-risk coronary artery disease receiving medical- and PCI- preceding therapies in Japan: J-SAP Study 1-1. Circ J 2006;70:365-9
   PubMed Web of Science ®Google Scholar
• Tokyo: Research group on economic evaluation for Japanese public medical benefits. Guideline for economic evaluation of healthcare technologies in Japan. 2013. http://hta.umin.jp/guideline_e.pdf. Accessed May 2016
   Google Scholar
• Hori M, Connolly SJ, Zhu J, et al. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 2013;44:1891-6
   PubMed Web of Science ®Google Scholar
• Wang Y, Xie F, Kong MC, et al. Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation. Cardiovasc Drugs Ther 2014;28:575-85
   PubMed Web of Science ®Google Scholar
• Lee S, Anglade MW, Pham D, et al. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol 2012;110:845-51
   PubMed Web of Science ®Google Scholar
• Mensch A, Stock S, Stollenwerk B, et al. Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation. Pharmacoeconomics 2015;33:271-83
   PubMed Web of Science ®Google Scholar
• Kleintjens J, Li X, Simoens S, et al. Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting. Pharmacoeconomics 2013;31:909-18
   PubMed Web of Science ®Google Scholar
• Morais J, Aguiar C, McLeod E, et al. Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting. Rev Port Cardiol 2014;33:535-44
   PubMedGoogle Scholar
• Kourlaba G, Maniadakis N, Andrikopoulos G, et al. Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece. Cost Eff Resour Alloc 2014;12:5
   PubMed Web of Science ®Google Scholar
• ten Cate H, Haas S, Accetta G, et al. Quality of vitamin K antagonist control and 1-year outcomes: a global perspective from the Garfield-AF registry. Int Soc Thromb Haemostas 2015;13(2 Suppl):130
   Google Scholar
• Nelson WW, Song X, Coleman CI, et al. Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Curr Med Res Opin 2014;30:2461-9
   PubMed Web of Science ®Google Scholar
• Evers T, O’Neil WM, Ogilvie IM, et al. Stroke prevention in patients with atrial fibrillation: inappropriate anticoagulation and poor INR control. Presented at the ISPOR 14th Annual European Congress, 5-8 Nov 2011, Madrid, Spain
   Google Scholar
• Shimizu H, Kawarai T, Saji N, et al. Re-evaluation of clinical feature and risk factors of acute ischemic stroke in Japanese longevity society. Kobe J Med Sci 2009;55:E132-9
   Google Scholar
• Ono A, Fujita T. Stroke prevention in patients with atrial fibrillation. J Clin Neurosci 2003;10:71-3
   PubMed Web of Science ®Google Scholar